分析公司Redeye下调了对医疗技术公司Xvivo Perfusion的估值，将其基本目标价从之前的425瑞典克朗降至385瑞典克朗，但仍维持对该公司的积极前景。周一，该股交易价格约为197瑞典克朗。 Redeye在一份委托分析报告中写道：“我们认为，在未来12个月内，这家新兴的利基市场领导者的股票有翻倍的潜力，这得益于市场情绪的改善和几个短期催化剂。” 该分析强调了Xvivo在体外灌注领域的领先 ...

Xvivo Perfusion AB (($XVIPF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled Direct Procurement ...

Xvivo Perfusion AB (publ) ( OTCPK:XVIPY) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT [Operator Instructions] The next question comes from Simon Larsson from Danske Bank.

Aims/Hypothesis: Beta-cell failure plays a fundamental role in type 2 diabetes mellitus (T2DM) development. It has been shown that the beta-cells are among the most sensitive to hypoxia. We aimed to ...

Xvivo Perfusion AB (($XVIPF)) announced an update on their ongoing clinical study. Study Overview: The study titled ‘PRESERVE CAP: A Prospective, ...

DALLAS, Aug. 7, 2025 /PRNewswire/ -- Integration Health today announced its official launch as the platform company unifying specialized ECMO, perfusion, and Normothermic Regional Perfusion (NRP) ...

The device, named HAPI for handheld laser perfusion imager, is based around laser speckle contrast imaging, in which the speckle effect caused by blood cells moving through blood vessels under laser ...